Welcome to LookChem.com Sign In|Join Free
  • or
Carbamic acid, [(1S)-1-[hydroxy(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]propyl]-, 1,1-dimethylethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

530123-55-8

Post Buying Request

530123-55-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

530123-55-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 530123-55-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,3,0,1,2 and 3 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 530123-55:
(8*5)+(7*3)+(6*0)+(5*1)+(4*2)+(3*3)+(2*5)+(1*5)=98
98 % 10 = 8
So 530123-55-8 is a valid CAS Registry Number.

530123-55-8Relevant academic research and scientific papers

NOVEL KETO-OXADIAZOLE DERIVATIVES AS CATHEPSIN INHIBITORS

-

Page/Page column 41, (2008/06/13)

Novel difluorinated amide derivatives of Formula (II) as inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 57, (2008/06/13)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page/Page column 47, (2010/02/09)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 530123-55-8